cellceutix - Home

cellceutix is an emerging bio-pharmaceutical company
focusing in the areas of cancer
and inflammatory disease...

Autism Compound, KM-391 Showing Significant Improvements On Key Parameters In Animal Studies

» Autism Study Results
» Press Release 3/29/2010
» Press Release 6/14/2010

See the previous CEO's Address here

American Association for Cancer Research (AACR) Debuts Frontiers in Basic Cancer Research Meeting

"Scientists at Cellceutix Corporation may have developed a new compound that could significantly delay lung tumor growth, according to data presented at the AACR Frontiers in Basic Cancer Research Meeting."

full article: http://www.aacr.org/home/public--media/aacr-press-releases.aspx?d=1584

Download Cellceutix Poster presented at AACR

Kevetrin^TM Demonstrates Significant Delay of Tumor Growth in Drug Resistant Breast Cancer

Kevetrin^TM Animal Model Testing Success Against Multi-Drug Resistant Lung Cancer

Cellceutix Compund KM-133 Shows Significant Effect On Psoriasis

Cellceutix Acquires New Compound for Autism

Cellceutix has acquired the rights to the compound KM 391, which it intends to pursue as a treatment for autism. KM 391 is a small molecule that was developed in India and will now be synthesized in the United States for continued testing. Read More...

From the desk of our CEO, George W. Evans, JD, MBA

Having passed the important milestone of our pre-IND meeting, it seems a good time to reflect on the last year for Cellceutix and to look ahead to the coming year. It is fair to say that we've come a long way. We believe that the coming year will be equally significant, if not more so.

At the beginning of last year, we were still figuring out which direction to take with our lead compound, Kevetrin (TM). We had some interesting data in head and neck cancer, but weren't sure if that was really the right way to go. Since then, we've filed our patent application, which covers Kevetrin and a large number of other related compounds. We've developed very interesting data in drug resistant lung, breast and colon cancer cell lines, which is encouraging given that these cancers are so difficult to treat. In fact, some of this data was presented at the American Association for Cancer Research (AACR) meeting in October. We've completed the synthesis of Active Pharmaceutical Ingredient under GMP conditions. And, after consultation with FDA, we've started the toxicity and safety pharmacology studies that will be needed for the IND filing.

Full Letter....